<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33522737</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1538-6899</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>27</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Continuum (Minneapolis, Minn.)</Title>
          <ISOAbbreviation>Continuum (Minneap Minn)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Myelitis and Other Autoimmune Myelopathies.</ArticleTitle>
        <Pagination>
          <StartPage>62</StartPage>
          <EndPage>92</EndPage>
          <MedlinePgn>62-92</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1212/CON.0000000000000900</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE OF REVIEW">This article provides an update on the clinical diagnosis and management of immune-mediated myelopathies, including the relevance of imaging, ancillary testing with an emphasis on autoantibody biomarkers, recognition of myelitis mimics, and therapeutic approach.</AbstractText>
          <AbstractText Label="RECENT FINDINGS">The imaging characterization of immune-mediated myelopathies and the discovery of neural autoantibodies have been crucial in improving our ability to accurately diagnose myelitis. The identification of autoantibodies directed against specific central nervous system targets has led to major improvements in our understanding of the mechanisms underlying inflammation in myelitis. It has also allowed distinction of these myelopathy etiologies from noninflammatory etiologies of myelopathy and from multiple sclerosis and provided insight into their risk of recurrence, treatment response, and long-term clinical outcomes. Prompt recognition and appropriate testing in the setting of acute and subacute myelopathies is critical as timely administration of immunotherapy can help improve symptoms and prevent permanent neurologic disability. A patient should not be classified as having "idiopathic transverse myelitis" without a comprehensive evaluation for a more specific etiology. Achieving the correct diagnosis and learning to recognize noninflammatory myelitis mimics is crucial as they have therapeutic and prognostic implications.</AbstractText>
          <AbstractText Label="SUMMARY">Identifying the clinical and radiographic features of immune-mediated myelitis and recognizing mimics and pitfalls will help clinicians treat confirmed autoimmune myelitis appropriately.</AbstractText>
          <CopyrightInformation>Copyright © 2021 American Academy of Neurology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lopez Chiriboga</LastName>
            <ForeName>Sebastian</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Flanagan</LastName>
            <ForeName>Eoin P</ForeName>
            <Initials>EP</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Continuum (Minneap Minn)</MedlineTA>
        <NlmUniqueID>9509333</NlmUniqueID>
        <ISSNLinking>1080-2371</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009188" MajorTopicYN="Y">Myelitis, Transverse</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013118" MajorTopicYN="Y">Spinal Cord Diseases</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>1</Day>
          <Hour>10</Hour>
          <Minute>7</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33522737</ArticleId>
        <ArticleId IdType="doi">10.1212/CON.0000000000000900</ArticleId>
        <ArticleId IdType="pii">00132979-202102000-00006</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Flanagan EP. Autoimmune myelopathies. Handb Clin Neurol 2016;133:327–351. doi:10.1016/B978-0-444-63432-0.00019-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/B978-0-444-63432-0.00019-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zalewski NL, Flanagan EP, Keegan BM. Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses. Neurology 2018;90(2):e96–e102. doi:10.1212/WNL.0000000000004796</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000004796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barreras P, Fitzgerald KC, Mealy MA, et al. Clinical biomarkers differentiate myelitis from vascular and other causes of myelopathy. Neurology 2018;90(1):e12–e21. doi:10.1212/WNL.0000000000004765</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000004765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barnes G, Benjamin S, Bowen JD, et al. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002;59(4):499–505. doi:10.1212/wnl.59.4.499</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/wnl.59.4.499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sechi E, Shosha E, Williams JP, et al. Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology. Neurology 2019;93(4):e414–e420 doi:10.1212/WNL.0000000000007828</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000007828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geraldes R, Ciccarelli O, Barkhof F, et al. The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nat Rev Neurol 2018;14(4):199–213. doi:10.1038/nrneurol.2018.14</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrneurol.2018.14</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 2019;15(2):89–102. doi:10.1038/s41582-018-0112-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41582-018-0112-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zalewski NL, Flanagan EP. Autoimmune and paraneoplastic myelopathies. Semin Neurol 2018;38:278–289. doi:10.1055/s-0038-1660856</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0038-1660856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flanagan EP, McKeon A, Lennon VA, et al. Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues. Neurology 2011;76(24):2089–2095. doi:10.1212/WNL.0b013e31821f468f</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e31821f468f</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy OC, Salazar-Camelo A, Jimenez JA, et al. Clinical and MRI phenotypes of sarcoidosis-associated myelopathy. Neurol Neuroimmunol Neuroinflamm 2020;7(4):e722. doi:10.1212/NXI.0000000000000722</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flanagan EP, Cabre P, Weinshenker BG, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol 2016;79(5):775–783. doi:10.1002/ana.24617</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.24617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zalewski NL, Rabinstein AA, Krecke KN, et al. Characteristics of spontaneous spinal cord infarction and proposed diagnostic criteria. JAMA Neurol 2019;76(1):56–63. doi:10.1001/jamaneurol.2018.2734</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2018.2734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keegan BM, Kaufmann TJ, Weinshenker BG, et al. Progressive solitary sclerosis: gradual motor impairment from a single CNS demyelinating lesion. Neurology 2016;87(16):1713–1719. doi:10.1212/WNL.0000000000003235</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000003235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sechi E, Keegan BM, Kaufmann TJ, et al. Unilateral motor progression in MS: association with a critical corticospinal tract lesion. Neurology 2019;93(7):e628–e634. doi:10.1212/WNL.0000000000007944</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000007944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flanagan EP, Hinson SR, Lennon VA, et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann Neurol 2017;81(2):298–309. doi:10.1002/ana.24881</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.24881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee CH, Bharwani L, Sullivan T. Paraneoplastic necrotizing myelopathy in a patient with newly diagnosed diffuse large B cell lymphoma. World J Oncol 2011;2:195–198. doi:10.4021/wjon279w</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4021/wjon279w</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flanagan EP. Neuromyelitis optica spectrum disorder and other non–multiple sclerosis central nervous system inflammatory diseases. Continuum (Minneap Minn) 2019;25(3):815–844. doi:10.1212/CON.0000000000000742</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/CON.0000000000000742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flanagan EP, Keegan BM. Paraneoplastic myelopathy. Neurol Clin 2013;31(1):307–318. doi:10.1016/j.ncl.2012.09.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ncl.2012.09.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flanagan EP, Kaufmann TJ, Krecke KN, et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol 2016;79(3):437–447. doi:10.1002/ana.24582</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.24582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salvarani C, Brown RD, Calamia KT, et al. Primary CNS vasculitis with spinal cord involvement. Neurology 2008;70(24 pt 2):2394–2400. doi:10.1212/01.wnl.0000314687.69681.24</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000314687.69681.24</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dimberg EL. Rheumatology and neurology. Continuum (Minneap Minn) 2017;23(3, Neurology of Systemic Disease):691–721. doi:10.1212/CON.0000000000000474</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/CON.0000000000000474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toledano M. Infectious myelopathies. Continuum (Minneap Minn) 2021;27(1, Spinal Cord Disorders):93–120.</Citation>
        </Reference>
        <Reference>
          <Citation>Zalewski NL. Vascular myelopathies. Continuum (Minneap Minn) 2021;27(1, Spinal Cord Disorders):30–61.</Citation>
        </Reference>
        <Reference>
          <Citation>Flanagan EP, Pittock SJ. Diagnosis and management of spinal cord emergencies. Handb Clin Neurol 2017;140:319–335. doi:10.1016/B978-0-444-63600-3.00017-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/B978-0-444-63600-3.00017-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savoldi F, Nasr Z, Hu W, et al. McArdle sign: a specific sign of multiple sclerosis. Mayo Clin Proc 2019;94(8):1427–1435. doi:10.1016/j.mayocp.2019.01.047</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mayocp.2019.01.047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hardy TA. Spinal cord anatomy and localization. Continuum (Minneap Minn) 2021;27(1, Spinal Cord Disorders):12–29.</Citation>
        </Reference>
        <Reference>
          <Citation>Sechi E, Krecke KN, Pittock SJ, et al. Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. Mult Scler 2020;1352458520907900. doi:10.1177/1352458520907900</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458520907900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filippi M, Preziosa P, Banwell BL, et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain 2019;142(7):1858–1875. doi:10.1093/brain/awz144</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awz144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klawiter EC, Benzinger T, Roy A, et al. Spinal cord ring enhancement in multiple sclerosis. Arch Neurol 2010;67(11):1395–1398. doi:10.1001/archneurol.2010.271</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneurol.2010.271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciccarelli O, Cohen JA, Reingold SC, et al. Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurol 2019:18(2):185–197. doi:10.1016/S1474-4422(18)30460-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(18)30460-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filippi M, Rossi P, Campi A, et al. Serial contrast-enhanced MR in patients with multiple sclerosis and varying levels of disability. AJNR Am J Neuroradiol 1997;18(8):1549–1556.</Citation>
        </Reference>
        <Reference>
          <Citation>Asnafi S, Morris PP, Sechi E, et al. The frequency of longitudinally extensive transverse myelitis in MS: a population-based study. Mult Scler Relat Disord 2020;37:101487. doi:10.1016/j.msard.2019.101487</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2019.101487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flanagan EP, Weinshenker BG, Krecke KN, et al. Short myelitis lesions in aquaporin-4-IgG–positive neuromyelitis optica spectrum disorders. JAMA Neurol 2015;72(1):81–87. doi:10.1001/jamaneurol.2014.2137</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2014.2137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciron J, Cobo-Calvo A, Audoin B, et al. Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: a retrospective multicentric study. Mult Scler 2019;1352458519849511. doi:10.1177/1352458519849511</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458519849511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar N, Frohman EM. Spinal neurosarcoidosis mimicking an idiopathic inflammatory demyelinating syndrome. Arch Neurol 2004;61(4):586–589. doi:10.1001/archneur.61.4.586</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.61.4.586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jitprapaikulsan J, Lopez Chiriboga AS, Flanagan EP, et al. Novel glial targets and recurrent longitudinally extensive transverse myelitis. JAMA Neurol 2018:e180805. doi:10.1001/jamaneurol.2018.0805</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2018.0805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zalewski NL, Morris PP, Weinshenker BG, et al. Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 2017;88(3):218–225. doi:10.1136/jnnp-2016-314738</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2016-314738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 2018;15(1):134. doi:10.1186/s12974-018-1144-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-018-1144-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>López-Chiriboga AS, Majed M, Fryer J, et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG–associated disorders. JAMA Neurol 2018;75(11):1355–1363. doi:10.1001/jamaneurol.2018.1814</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2018.1814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubey D, Pittock SJ, Krecke KN, et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol 2019;76(3):301–309. doi:10.1001/jamaneurol.2018.4053</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2018.4053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012;79(12):1273–1277. doi:10.1212/WNL.0b013e31826aac4e</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e31826aac4e</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zalewski NL, Krecke KN, Weinshenker BG, et al. Central canal enhancement and the trident sign in spinal cord sarcoidosis. Neurology 2016;87(7):743–744. doi:10.1212/WNL.0000000000002992</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000002992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boban J, Thurnher MM. Ventral-subpial enhancement in spinal cord sarcoidosis: a braid-like sign. Neurology 2018;10.1212/WNL.0000000000006857. doi:10.1212/WNL.0000000000006857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000006857.</ArticleId>
            <ArticleId IdType="doi">10.1212/WNL.0000000000006857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uygunoglu U, Zeydan B, Ozguler Y, et al. Myelopathy in Behçet's disease: the Bagel sign. Ann Neurol 2017;82(2):288–298. doi:10.1002/ana.25004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.25004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sechi E, Morris PP, McKeon A, et al. Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis. J Neurol Neurosurg Psychiatry 2019;90(4):488–490. doi:10.1136/jnnp-2018-318004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2018-318004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogawa R, Nakashima I, Takahashi T, et al. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol NeuroInflamm 2017;4(2):e322. doi:10.1212/NXI.0000000000000322</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Budhram A, Mirian A, Le C, et al. Unilateral cortical FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome. J Neurol 2019;266(10):2481–2487. doi:10.1007/s00415-019-09440-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-019-09440-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dutra BG, José da Rocha A, Nunes RH, Martins Maia Júnior C. Neuromyelitis optica spectrum disorders: spectrum of MR imaging findings and their differential diagnosis–erratum. Radiographics 2018;38(2):662. doi:10.1148/rg.2018184002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/rg.2018184002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mariotto S, Gajofatto A, Batzu L, et al. Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases. Neurology 2019;93(20):e1867–e1872. doi:10.1212/WNL.0000000000008479</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000008479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waters PJ, Komorowski L, Woodhall M, et al. A multicenter comparison of MOG-IgG cell-based assays. Neurology 2019;92(11):e1250–e1255. doi:10.1212/WNL.0000000000007096</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000007096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kunchok A, Chen JJ, McKeon A, et al. Coexistence of myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies in adult and pediatric patients. JAMA Neurol 2019;77(2):257–259. doi:10.1001/jamaneurol.2019.3656</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2019.3656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faissner S, Lukas C, Reinacher-Schick A, et al. Amphiphysin-positive paraneoplastic myelitis and stiff-person syndrome. Neurol Neuroimmunol Neuroinflamm 2016;3(6):e285. doi:10.1212/NXI.0000000000000285</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honorat JA, Sebastian Lopez-Chiriboga A, Kryzer TJ, et al. Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG. Neurology 2019;93(10):954–963. doi:10.1212/WNL.0000000000008061</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000008061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hinson SR, Lopez-Chiriboga AS, Bower JH, et al. Glycine receptor modulating antibody predicting treatable stiff-person spectrum disorders. Neurol Neuroimmunol Neuroinflamm 2018;5(2):e438. doi:10.1212/NXI.0000000000000438</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shelly S, Kryzer TJ, Komorowski L, et al. Neurochondrin neurological autoimmunity. Neurol Neuroimmunol Neuroinflamm 2019;6(6):e612. doi:10.1212/NXI.0000000000000612</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alfugham N, Gadoth A, Lennon VA, et al. ITPR1 autoimmunity: frequency, neurologic phenotype, and cancer association. Neurol Neuroimmunol Neuroinflamm 2018;5(1):e418. doi:10.1212/NXI.0000000000000418</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basal E, Zalewski N, Kryzer TJ, et al. Paraneoplastic neuronal intermediate filament autoimmunity. Neurology 2018;91(18):e1677–e1689. doi:10.1212/WNL.0000000000006435</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000006435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guerra H, Pittock SJ, Moder KG, et al. Frequency of aquaporin-4 immunoglobulin g in longitudinally extensive transverse myelitis with antiphospholipid antibodies. Mayo Clin Proc 2018;93(9):1299–1304. doi:10.1016/j.mayocp.2018.02.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mayocp.2018.02.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takano R, Misu T, Takahashi T, et al. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 2010;75(3):208–216. doi:10.1212/WNL.0b013e3181e2414b</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3181e2414b</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikeda K, Kiyota N, Kuroda H, et al. Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody. Mult Scler 2015;21(5):656–659. doi:10.1177/1352458514551455</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458514551455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu X, Li W, Deng Q, et al. MYD88 L265P mutation in lymphoid malignancies. Cancer Res 2018;78(10):2457–2462. doi:10.1158/0008-5472.CAN-18-0215</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-18-0215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKeon A, Apiwattanakul M, Lachance DH, et al. Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review. Arch Neurol 2010;67(3):322–329. doi:10.1001/archneurol.2009.336</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneurol.2009.336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock SJ, Lennon VA. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol 2008;65(5):629–632. doi:10.1001/archneur.65.5.629</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.65.5.629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen-Gadol AA, Zikel OM, Miller GM, et al. Spinal cord biopsy: a review of 38 cases. Neurosurgery 2003;52(4):806–815; discussion 815-816. doi:10.1227/01.neu.0000053223.77641.5e.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1227/01.neu.0000053223.77641.5e</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flanagan EP, Krecke KN, Marsh RW, et al. Specific pattern of gadolinium enhancement in spondylotic myelopathy. Ann Neurol 2014;76(1):54–65. doi:10.1002/ana.24184</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.24184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conway BL, Clarke MJ, Kaufmann TJ, Flanagan EP. Utility of extension views in spondylotic myelopathy mimicking transverse myelitis. Mult Scler Relat Disord 2017;11:62–64. doi:10.1016/j.msard.2016.12.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2016.12.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46(6):878–886. doi:10.1002/1531-8249(199912)46:6&lt;878::aid-ana10&gt;3.0.co;2-q</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1531-8249(199912)46:6&lt;878::aid-ana10&gt;3.0.co;2-q</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abboud H, Petrak A, Mealy M, et al. Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler J 2016;22(2):185–192. doi:10.1177/1352458515581438</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458515581438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2018;89(4):346–351. doi:10.1136/jnnp-2017-316286</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2017-316286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gross RH, Corboy JR. Monitoring, switching, and stopping multiple sclerosis disease-modifying therapies. Continuum (Minneap Minn) 2019;25(3):715–735. doi:10.1212/CON.0000000000000738</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/CON.0000000000000738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 2019;381(7):614–625. doi:10.1056/NEJMoa1900866</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1900866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 2019;394(10206):1352–1363. doi:10.1016/S0140-6736(19)31817-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(19)31817-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2020;19:298–306. doi:10.1016/S1474-4422(20)30066-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(20)30066-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 2019;381(22):2114–2124. doi:10.1056/NEJMoa1901747</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1901747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez-Chiriboga S, Sechi E, Buciuc M, et al. Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder. JAMA Neurol 2020;31:e203115. doi:10.1001/jamaneurol.2020.3115</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2020.3115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen JJ, Flanagan EP, Bhatti MT, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology 2020;95(2):e111–e120. doi:10.1212/WNL.0000000000009758</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000009758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gelfand JM, Bradshaw MJ, Stern BJ, et al. Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series. Neurology 2017;89(20):2092–2100. doi:10.1212/WNL.0000000000004644</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000004644</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
